Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 101Leukemia 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Myelodysplastic Syndromes 83Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Hodgkin Disease 67Lymphoma, Mantle-Cell 63Lymphoma 62Lymphoma, Large B-Cell, Diffuse 60Lymphoma, Follicular 59Leukemia, Myeloid, Chronic-Phase 57Lymphoma, B-Cell, Marginal Zone 53Burkitt Lymphoma 53Lymphoma, Large-Cell, Immunoblastic 49Leukemia, Myeloid, Accelerated Phase 48Congenital Abnormalities 48Myeloproliferative Disorders 46Leukemia, Myelomonocytic, Chronic 43Anemia, Refractory, with Excess of Blasts 41Graft vs Host Disease 37Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Blast Crisis 33Recurrence 32Dendritic Cell Sarcoma, Interdigitating 32Primary Myelofibrosis 27Lymphoma, T-Cell, Cutaneous 27Neoplasms, Plasma Cell 26Waldenstrom Macroglobulinemia 25

Interventions

Tacrolimus 1Phlebotomy 1Cyclosporins 1Cyclosporine 1Blood Specimen Collection 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymic aplasia × Cyclosporine × Clear all
NCT02274662 2025-01-16

Expanded Access Protocol Thymus Transplantation

Sumitomo Pharma Switzerland GmbH

Phase 4 Completed
11 enrolled 10 charts

Thymic aplasia, Immunologic Deficiency Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡